Form 4: Dynavax Director Daniel Kisner Reports Significant Equity Grant

Dynavax Technologies Corp. Director Daniel L. Kisner has reported the acquisition of 5,758 restricted stock units and 28,500 stock options, granted as compensation.

Summary

• Daniel L. Kisner, a Director of Dynavax Technologies Corp. (DVAX), reported new equity grants on June 11, 2025.
• He acquired 5,758 shares of Common Stock in the form of Restricted Stock Units (RSUs) at a grant price of $0.
• He also acquired 28,500 Stock Options with an exercise price of $10.18 per share, also granted at $0.
• Following these transactions, Mr. Kisner beneficially owns 23,329 shares of Common Stock (including RSUs) and 28,500 Stock Options.
• Both the RSUs and stock options are scheduled to fully vest one year from the grant date (June 11, 2025), contingent on his continued service to the company.
• The release of RSU shares will be mandatorily deferred for six months and one day after Mr. Kisner no longer provides services to the company.
• The granted stock options have an expiration date of June 10, 2032.

Sentiment

Score: 7

Explanation: The grant of equity compensation to a director is a positive sign of alignment between management and shareholder interests, incentivizing long-term performance.

Positives

• The grant of 5,758 Restricted Stock Units (RSUs) and 28,500 stock options to Director Daniel L. Kisner aligns his interests directly with those of shareholders, as his compensation is tied to the company's future performance.
• The vesting schedule, requiring one year of continued service, incentivizes long-term commitment and retention from a key board member.

Negatives

• No inherent negatives are present in this standard compensation disclosure.

Risks

• NA

Future Outlook

The RSUs and stock options are scheduled to fully vest one year from the grant date (June 11, 2025), provided the reporting person continues to provide services to the company. The release of RSU shares will be mandatorily deferred six months and one day after the reporting person ceases to provide services.

Management Comments

• NA

Industry Context

This Form 4 filing is a routine disclosure of insider compensation, common across all publicly traded companies. It reflects standard practices for aligning executive and director incentives with shareholder value through equity grants.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• The transaction involves the grant of equity compensation to Daniel L. Kisner, a Director of Dynavax Technologies Corp., which is a common form of related party transaction for executive and director remuneration.

Stakeholder Impact

• Shareholders: The equity grants align the interests of Director Daniel L. Kisner with those of shareholders, as his compensation is tied to the company's stock performance, potentially encouraging decisions that enhance shareholder value.
• Employees: While not directly impacting all employees, the compensation structure for directors can reflect the company's overall approach to incentivizing its leadership.

Next Steps

• RSUs and stock options will vest one year from the grant date (June 11, 2025), contingent on continued service.

Key Dates

Keywords

Dynavax, DVAX, SEC Form 4, insider transaction, stock options, restricted stock units, equity grant, director compensation